Search
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Fortune 500
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Eli Lilly
Eli Lilly
Health
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic
By
Nick Lichtenberg
November 6, 2025
Health
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By
Matty Merritt
and
Morning Brew
October 31, 2025
Eli Lilly (LLY) Q3 2025 Earnings Call Transcript
By
Fortune Editors
October 30, 2025
Eli Lilly (LLY) Q2 2025 Earnings Call Transcript
By
Fortune Editors
August 7, 2025
Tech
Novo ousts CEO Jorgensen after Lilly competition hits shares
By
Eric Pfanner
and
Bloomberg
May 16, 2025
Health
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
By
Jonel Aleccia
and
The Associated Press
May 12, 2025
Eli Lilly (LLY) Q1 2025 Earnings Call Transcript
By
Fortune Editors
May 1, 2025
Politics
Viagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.
By
Ryan Hogg
April 30, 2025
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By
Marthe Fourcade
and
Bloomberg
April 22, 2025
Retail
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
By
Paula Doenecke
,
Naomi Kresge
and
Bloomberg
March 12, 2025
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By
Wendy Barnes
March 4, 2025
Finance
Eli Lilly to spend $27 billion to bolster U.S. drug manufacturing as Trump tariffs loom
By
Madison Muller
and
Bloomberg
February 26, 2025
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By
Bloomberg
,
Madison Muller
,
Ike Swetlitz
and
Naomi Kresge
February 21, 2025
Finance
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
By
Ryan Hogg
February 19, 2025
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By
Lindsey Leake
February 11, 2025
Most Popular
AI
Russia's first AI-powered robot walked on stage to triumphant music, took a few steps, and then immediately faceplanted
By
Dave Smith
Future of Work
Ford CEO says he has 5,000 open mechanic jobs with 6-figure salaries from the shortage of manually skilled workers: 'We...
By
Marco Quiroz-Gutierrez
Economy
'We are guilty of spending our rainy-day fund in sunny weather': Top economists, historians unite to urge action on $38...
By
Nick Lichtenberg